Fátima De la Cruz

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 324 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +4

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)

Ramón García‐Sánz, Anna Sureda, Fátima De la Cruz et al. · Annals of Oncology · 2019 · 121 citations · Full text

Tracking of food and nutrient intake from adolescence into early adulthood

Fátima De la Cruz, Elisabete Ramos, Carla Lopes et al. · Nutrition · 2018 · 78 citations

Obesity, Nutrition, Childhood Obesity +9

Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma

Monica Else, Ana Marín‐Niebla, Fátima De la Cruz et al. · British Journal of Haematology · 2012 · 76 citations

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Eva Giné, Fátima De la Cruz, Ana Jiménez Ubieto et al. · Journal of Clinical Oncology · 2022 · 57 citations · Full text